research use only

BAY 41-2272 Guanylate Cyclase agonist

Cat.No.S8128

BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.

Chemical Structure

Molecular Weight: 360.39

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S812801 DMSO]35 mg/mL]false]Ethanol]4 mg/mL]false]Water]Insoluble]false Purity: 99.96%

99.96

Related Targets	Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras GPR GluR Prostaglandin Receptor CXCR Adenosine Receptor P2 Receptor CCR Angiotensin Receptor Hedgehog/Smoothened S1P Receptor PKA Cannabinoid Receptor cAMP Glucagon Receptor SGLT Opioid Receptor Sigma Receptor PAR Endothelin Receptor LTR Neurokinin Receptor PKG LPA Receptor OX Receptor
Related Products	ODQ Indusatumab (Anti-GUCY2C) GUCY1B3 Antibody [G11K4] Indusatumab vedotin

Chemical Information, Storage & Stability

Molecular Weight	360.39	Formula	C₂₀H₁₇FN₆	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	256376-24-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1CC1C2=CN=C(N=C2N)C3=NN(C4=C3C=CC=N4)CC5=CC=CC=C5F

Solubility

In vitro
Batch:

DMSO : 35 mg/mL (97.11 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 4 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.875mg/ml (2.43mM)	Taking the 1 mL working solution as an example, add 50 μL of 17.5 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.580mg/ml (1.61mM)	Taking the 1 mL working solution as an example, add 50 μL of 11.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Guanylate cyclase ^[1]
In vitro	In vitro, BAY 41-2272 results in concentration dependent relaxation of human and rabbit cavernosum with EC50 of 489.1 nM and 406.3 nM, respectively. ^[3]
In vivo	In female spontaneously hypertensive rats, BAY 41-2272 (10 mg/kg, p.o.) shows antiplatelet effect, strongly decreases blood pressure and increases survival. ^[2] In C. albicans-infected mice, this compound (10 mg/kg, i.p.) markedly increases macrophage-dependent cell influx to the peritoneum in addition to macrophage functions, and reduces the death rate. ^[4] In db/db-/- type II diabetic and obese mice, this chemical improves impaired corpus cavernosum (CC) relaxation. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/11801189/ [2] https://pubmed.ncbi.nlm.nih.gov/11242081/ [3] https://pubmed.ncbi.nlm.nih.gov/12544359/ [4] https://pubmed.ncbi.nlm.nih.gov/25742266/ [5] https://pubmed.ncbi.nlm.nih.gov/25740897/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):